This series offers reviews of the latest advances from recent scientific meetings.
24 Months with Pirfenidone and Nintedanib: What Have We Learned?
Care of patients with IPF has been transformed since the 2014 FDA approval of pirfenidone and nintedanib for the treatment of patients with IPF. Providers considering these treatments for their patients face decisions of which protocol is best for an individual patient, when to start, switch or combine treatments, and how to manage side effects and dosing. Explore real-world issues of treating patients with IPF. Presented in Los Angeles, California - October 2016.
Presented by: Paul W. Noble, MD and Jonathan Goldin, PhD, MD
Additional Case-based CME
Toni: Too tired to continue teaching and experiencing painful heartburn
Further clinical examination helps resolve curious HRCT findings. Join Alison G. Wilcox, MD, FSCCT in the diagnosis of this retired teacher.
Elizabeth: Loves the outdoors but bothered by persistent cough and GERD
Luca Richeldi, MD, PhD and Alison G. Wilcox, MD, FSCCT consider the case of a Colorado woman with an active lifestyle. How does the multidisciplinary team arrive at a diagnosis?
Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs
Paul W. Noble, MD and Alison G. Wilcox, MD, FSCCT consider a woman presenting with dry cough and dyspnea. They show how radiology and clinical factors contribute to an accurate diagnosis.
NSCLC–Pulmonologists as the Gatekeepers of Precision Medicine: How Much is Enough Tissue?
Presented by: Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD
Biomarker-driven targeted therapy of patients with NSCLC requires accurate diagnosis and staging. The pulmonary care team must acquire adequate biopsy tissue to enable histology, immunofluorescence and molecular biomarker testing. Presented in Los Angeles, California - October 2016.
Exciting Developments from 2015 CHEST
Steven Nathan, MD
Inova Fairfax Hospital
Dr. Nathan highlights exciting developments were presented at CHEST.
New Trends in IPF
Luca Richeldi, MD, PhD
University of Southampton
Dr. Richeldi addresses the following questions:
- What developments in treatment of IPF were presented at the PFF annual meeting?
- What is the role of patient registries in IPF?
- Have there been any clinical studies of pirfenidone combined with nintedanib?
Exciting Developments from 2015 ERS
Steven Nathan, MD
Inova Fairfax Hospital
Dr. Nathan highlights exciting developments were presented at ERS.
Biomarkers for IPF
Naftali Kaminski, MD
Yale School of Medicine
Dr. Kaminski addresses the following questions:
- Which biomarkers have been investigated for IPF?
- Are there biomarkers that help diagnosis of IPF?
- Are there biomarkers for prognosis or monitoring of IPF?
- Can biomarkers influence disease management choices?
- Is there a role for genetic testing in IPF?
Discovering New Drugs for IPF
Andrew M. Tager, MD
Harvard Medical School
Dr. Tager addresses the following questions:
- How do nintedanib and pirfenidone work?
- Which targets are being investigated in the search for new drugs?
- Which drug candidates might emerge in the near future?
- Are there drugs for other indications that might be useful for IPF?
David J. Lederer, MD, MS, and Ganesh Raghu, MD, FACP, FCCP discuss the following topics:
- Exciting news from ATS 2015
- Anticipated results from ATS 2016
Highlights from ATS 2014: Discussions on Clinical Trial Data
ASCEND, INPULSIS, and PANTHER are further covered in a roundtable format. Our experts explore the clinical endpoints, inclusion criteria, and clinical implications of these recent trials. The clinical use of drug combinations is also discussed.
Harold R. Collard, MD (Co-Chair, Moderator); Luca Richeldi, MD, PhD (Co-Chair); Vincent Cottin, MD, PhD; Sonye K. Danoff, MD, PhD; David Lederer, MD, MS
Highlights from ATS 2014: Top Line Clinical Trial Results - ASCEND, INPULSIS, and PANTHER
ASCEND, INPULSIS, and PANTHER are random controlled clinical trials of emerging therapies for IPF. Three experts present the study design, inclusion criteria, and results of these trials.
Harold R. Collard, MD; David Lederer, MD, MS; Luca Richeldi, MD, PhD
Highlights from ATS 2014: Update on Predicting Clinical Progression
Our expert panel discusses new developments in biomarkers of IPF and disease progression. Studies of familial IPF reveal biochemical changes in the absence of clinical disease.
Luca Richeldi, MD, PhD (Co-Chair, Moderator); Harold R. Collard, MD (Co-Chair); Vincent Cottin, MD, PhD; Sonye K. Danoff, MD, PhD; David Lederer, MD, MS